Literature DB >> 18449007

Tissue heterogeneity of EGFR mutation in lung adenocarcinoma.

Akira Sakurada1, Humberto Lara-Guerra, Ni Liu, Frances A Shepherd, Ming-Sound Tsao.   

Abstract

Tissue heterogeneity of EGFR gene mutation was studied in 10 formalin-fixed paraffin-embedded (FFPE) samples from four cases that demonstrated EGFR mutations in snap-frozen samples. EGFR mutations identical to those in frozen sample were demonstrated in 8 of 10 FFPE samples by direct sequencing and in 9 of 10 by fragment length analysis, but an exon-19 deletion mutation could not be identified in one FFPE sample analyzed by both techniques, despite multiple repeated assays. This suggests that some tumors may demonstrate intratumoral heterogeneity for the occurrence of EGFR mutation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449007     DOI: 10.1097/JTO.0b013e318168be93

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  24 in total

1.  The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer.

Authors:  Jingya Zhao; Xiaoying Wang; Liang Xue; Nuo Xu; Xin Ye; Haiying Zeng; Shaohua Lu; Jie Huang; Sujie Akesu; Chen Xu; Deming He; Yunshan Tan; Qunying Hong; Qun Wang; Guanshan Zhu; Yingyong Hou; Xin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2014-02-22       Impact factor: 4.553

Review 2.  Surgery for NSCLC in the era of personalized medicine.

Authors:  Tetsuya Mitsudomi; Kenichi Suda; Yasushi Yatabe
Journal:  Nat Rev Clin Oncol       Date:  2013-02-26       Impact factor: 66.675

3.  MassARRAY, pyrosequencing, and PNA clamping for EGFR mutation detection in lung cancer tissue and cytological samples: a multicenter study.

Authors:  Kyueng-Whan Min; Wan-Seop Kim; Se Jin Jang; Yoo Duk Choi; Sunhee Chang; Soon Hee Jung; Lucia Kim; Mee-Sook Roh; Choong Sik Lee; Jung Weon Shim; Mi Jin Kim; Geon Kook Lee
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

4.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

5.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity.

Authors:  Noemi Andor; Trevor A Graham; Marnix Jansen; Li C Xia; C Athena Aktipis; Claudia Petritsch; Hanlee P Ji; Carlo C Maley
Journal:  Nat Med       Date:  2015-11-30       Impact factor: 53.440

6.  Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.

Authors:  Katsuhiko Shimizu; Takuro Yukawa; Yuji Hirami; Riki Okita; Shinsuke Saisho; Ai Maeda; Koichiro Yasuda; Masao Nakata
Journal:  Target Oncol       Date:  2012-12-05       Impact factor: 4.493

7.  High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.

Authors:  Likun Hou; Shengxiang Ren; Bo Su; Liping Zhang; Wei Wu; Wei Zhang; Zhengwei Dong; Yan Huang; Chunyan Wu; Gang Chen
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  Immunohistochemistry with a novel mutation-specific monoclonal antibody as a screening tool for the EGFR L858R mutational status in primary lung adenocarcinoma.

Authors:  Wei Ping; Chunjiao Xia; Shengling Fu; Yixin Cai; Yu Deng; Wei Sun; Cuiping Dong; Xiangning Fu
Journal:  Tumour Biol       Date:  2014-10-07

9.  Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer.

Authors:  Fernando Lopez-Rios; Barbara Angulo; Belen Gomez; Debbie Mair; Rebeca Martinez; Esther Conde; Felice Shieh; Julie Tsai; Jeffrey Vaks; Robert Current; H Jeffrey Lawrence; David Gonzalez de Castro
Journal:  J Clin Pathol       Date:  2013-02-05       Impact factor: 3.411

10.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.

Authors:  A Kalikaki; A Koutsopoulos; M Trypaki; J Souglakos; E Stathopoulos; V Georgoulias; D Mavroudis; A Voutsina
Journal:  Br J Cancer       Date:  2008-09-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.